FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794061572> ?p ?o ?g. }

• W2794061572 endingPage "e479" @default.
• W2794061572 startingPage "e465" @default.
• W2794061572 abstract "BackgroundAfatinib is approved in the US, Europe, and several other regions for first-line treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC).Patients and MethodsTreatment-naive patients with advanced EGFRm+ NSCLC were randomized to afatinib (40 mg/d) versus cisplatin/pemetrexed (LUX-Lung 3 [LL3]) or cisplatin/gemcitabine (LUX-Lung 6 [LL6]), or versus gefitinib (250 mg/d; LUX-Lung 7 [LL7]). We report subgroup analyses according to age, including 65 years or older versus younger than 65 years (preplanned; LL3/LL6) and additional cutoffs up to 75 years and older (exploratory; LL7). Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated.ResultsAmong the 134 of 345 (39%) and 86 of 364 (24%) patients aged 65 years and older in LL3 and LL6, median PFS was improved with afatinib versus chemotherapy (LL3: hazard ratio [HR], 0.64 [95% confidence interval (CI), 0.39-1.03]; LL6: HR, 0.16 [95% CI, 0.07-0.39]). Afatinib significantly improved OS versus chemotherapy in elderly patients with Del19+ NSCLC in LL3 (HR, 0.39 [95% CI, 0.19-0.80]). Among the 40 of 319 patients (13%) aged 75 years or older in LL7, median PFS (HR, 0.69 [95% CI, 0.33-1.44]) favored afatinib, consistent with the overall population. Afatinib-associated AEs in older patients were consistent with the overall populations.ConclusionsSubgroup analyses of the LL3, LL6, and LL7 trials show that afatinib is an effective and tolerable treatment for patients with EGFRm+ NSCLC, independent of age." @default.
• W2794061572 created "2018-03-29" @default.
• W2794061572 creator A5005962138 @default.
• W2794061572 creator A5027105537 @default.
• W2794061572 creator A5027877389 @default.
• W2794061572 creator A5030107272 @default.
• W2794061572 creator A5032337115 @default.
• W2794061572 creator A5032833474 @default.
• W2794061572 creator A5033519199 @default.
• W2794061572 creator A5036507802 @default.
• W2794061572 creator A5038306289 @default.
• W2794061572 creator A5043397424 @default.
• W2794061572 creator A5052670273 @default.
• W2794061572 creator A5052765751 @default.
• W2794061572 creator A5052962058 @default.
• W2794061572 creator A5053546904 @default.
• W2794061572 creator A5059278629 @default.
• W2794061572 creator A5066716873 @default.
• W2794061572 creator A5066717752 @default.
• W2794061572 creator A5075333926 @default.
• W2794061572 creator A5077287358 @default.
• W2794061572 creator A5083475804 @default.
• W2794061572 creator A5091073688 @default.
• W2794061572 date "2018-07-01" @default.
• W2794061572 modified "2023-10-18" @default.
• W2794061572 title "Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials" @default.
• W2794061572 cites W1888630691 @default.
• W2794061572 cites W2060758966 @default.
• W2794061572 cites W2094532260 @default.
• W2794061572 cites W2096198395 @default.
• W2794061572 cites W2132870547 @default.
• W2794061572 cites W2133149289 @default.
• W2794061572 cites W2135192471 @default.
• W2794061572 cites W2149733252 @default.
• W2794061572 cites W2152327189 @default.
• W2794061572 cites W2163351155 @default.
• W2794061572 cites W2165661838 @default.
• W2794061572 cites W2171139285 @default.
• W2794061572 cites W2210071992 @default.
• W2794061572 cites W2254368272 @default.
• W2794061572 cites W2268675562 @default.
• W2794061572 cites W2281930375 @default.
• W2794061572 cites W2339311613 @default.
• W2794061572 cites W2512922897 @default.
• W2794061572 cites W2587420003 @default.
• W2794061572 cites W2604523713 @default.
• W2794061572 cites W2728649122 @default.
• W2794061572 cites W2760639821 @default.
• W2794061572 doi "https://doi.org/10.1016/j.cllc.2018.03.009" @default.
• W2794061572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29653820" @default.
• W2794061572 hasPublicationYear "2018" @default.
• W2794061572 type Work @default.
• W2794061572 sameAs 2794061572 @default.
• W2794061572 citedByCount "50" @default.
• W2794061572 countsByYear W27940615722018 @default.
• W2794061572 countsByYear W27940615722019 @default.
• W2794061572 countsByYear W27940615722020 @default.
• W2794061572 countsByYear W27940615722021 @default.
• W2794061572 countsByYear W27940615722022 @default.
• W2794061572 countsByYear W27940615722023 @default.
• W2794061572 crossrefType "journal-article" @default.
• W2794061572 hasAuthorship W2794061572A5005962138 @default.
• W2794061572 hasAuthorship W2794061572A5027105537 @default.
• W2794061572 hasAuthorship W2794061572A5027877389 @default.
• W2794061572 hasAuthorship W2794061572A5030107272 @default.
• W2794061572 hasAuthorship W2794061572A5032337115 @default.
• W2794061572 hasAuthorship W2794061572A5032833474 @default.
• W2794061572 hasAuthorship W2794061572A5033519199 @default.
• W2794061572 hasAuthorship W2794061572A5036507802 @default.
• W2794061572 hasAuthorship W2794061572A5038306289 @default.
• W2794061572 hasAuthorship W2794061572A5043397424 @default.
• W2794061572 hasAuthorship W2794061572A5052670273 @default.
• W2794061572 hasAuthorship W2794061572A5052765751 @default.
• W2794061572 hasAuthorship W2794061572A5052962058 @default.
• W2794061572 hasAuthorship W2794061572A5053546904 @default.
• W2794061572 hasAuthorship W2794061572A5059278629 @default.
• W2794061572 hasAuthorship W2794061572A5066716873 @default.
• W2794061572 hasAuthorship W2794061572A5066717752 @default.
• W2794061572 hasAuthorship W2794061572A5075333926 @default.
• W2794061572 hasAuthorship W2794061572A5077287358 @default.
• W2794061572 hasAuthorship W2794061572A5083475804 @default.
• W2794061572 hasAuthorship W2794061572A5091073688 @default.
• W2794061572 hasBestOaLocation W27940615721 @default.
• W2794061572 hasConcept C121608353 @default.
• W2794061572 hasConcept C126322002 @default.
• W2794061572 hasConcept C143998085 @default.
• W2794061572 hasConcept C207103383 @default.
• W2794061572 hasConcept C2776256026 @default.
• W2794061572 hasConcept C2776694085 @default.
• W2794061572 hasConcept C2777240266 @default.
• W2794061572 hasConcept C2777714996 @default.
• W2794061572 hasConcept C2778239845 @default.
• W2794061572 hasConcept C2779438470 @default.
• W2794061572 hasConcept C2780258809 @default.
• W2794061572 hasConcept C2780580887 @default.
• W2794061572 hasConcept C2780586478 @default.
• W2794061572 hasConcept C2908647359 @default.
• W2794061572 hasConcept C44249647 @default.

• next